Tuba ÇELEN YOLDAŞ, Elif Nur ÖZMERT, Berrak BİLGİNER GÜRBÜZ, Halil Tuna AKAR, Turgay COŞKUN

Autism spectrum disorder in patients with inherited metabolic disorders-a large sample from a tertiary center

Background. There is increased awareness regarding the co-occurrence of autism spectrum disorder (ASD) and inherited metabolic disorders (IMD), and this is crucial for the management of both diagnoses in clinical practice. We aimed firstly to report twenty-two patients with a dual diagnosis of IMD and ASD who are still being followed up in the child metabolism outpatient clinic; secondly to evaluate the time of both IMD and ASD diagnosis and the clinical progress of their metabolic disorders to underline treatable conditions. Methods. Among the patients admitted to the Pediatric Metabolism outpatient clinic because of IMD, twentytwo of them who had a diagnosis of ASD were included in the study. Data of the patients were collected from their medical records. The most recent progress of the patients concerning their metabolic disorder was obtained from the patients’ files. Results. Six cases with Phenylketonuria, 2 cases with partial Biotinidase Deficiency, 3 cases with Cerebral Creatine Deficiency Syndrome (CCDS), 5 cases with Mucopolysaccharidosis (MPS) Type-3b, 2 cases with MPS Type-3a, 1 case with MPS Type 4, 2 cases with Hypervalinemia and 1 case with Maple Syrup Urine Disease were all diagnosed as also having ASD. The diagnoses of CCDS and MPS Type 3 were after the diagnosis of ASD. Phenylketonuria and Mucopolysaccharidosis were the most common diagnoses in our study. In addition, rare entities such as MPS Type 3b and Type 4 and Hypervalinemia were also reported to co-occur with autism. Conclusions. Considering the co-occurrence of both disorders and implementing intervention strategies accordingly will certainly be beneficial in clinical practice and particularly in countries with a high rate of consanguinity

PDF

___

1. Lappe M, Lau L, Dudovitz RN, Nelson BB, Karp EA, Kuo AA. The diagnostic odyssey of autism spectrum disorder. Pediatrics 2018; 141(Suppl 4): S272-S279.

2. Ghaziuddin M, Al-Owain M. Autism spectrum disorders and inborn errors of metabolism: an update. Pediatr Neurol 2013; 49: 232-236.

3. Simons A, Eyskens F, Glazemakers I, van West D. Can psychiatric childhood disorders be due to inborn errors of metabolism? Eur Child Adolesc Psychiatry 2017; 26: 143-154.

4. Sedel F, Baumann N, Turpin JC, Lyon-Caen O, Saudubray JM, Cohen D. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis 2007; 30: 631-641.

5. Wertheim-Tysarowska K, Gos M, Sykut-Cegielska J, Bal J. Genetic analysis in inherited metabolic disorders--from diagnosis to treatment. Own experience, current state of knowledge and perspectives. Dev Period Med 2015; 19: 413-431.

6. Al-Owain M, Al-Zaidan H, Al-Hassnan Z. Map of autosomal recessive genetic disorders in Saudi Arabia: concepts and future directions. Am J Med Genet A 2012; 158A: 2629-2640.

7. Schiff M, Benoist JF, Aissaoui S, et al. Should metabolic diseases be systematically screened in nonsyndromic autism spectrum disorders? PLoS One 2011; 6: e21932.

8. Kiykim E, Zeybek CA, Zubarioglu T, et al. Inherited metabolic disorders in Turkish patients with autism spectrum disorders. Autism Res 2016; 9: 217-223.

9. Zablotsky B, Colpe LJ, Pringle BA, Kogan MD, Rice C, Blumberg SJ. Age of parental concern, diagnosis, and service initiation among children with autism spectrum disorder. Am J Intellect Dev Disabil 2017; 122: 49-61.

10. Maenner MJ, Schieve LA, Rice CE, et al. Frequency and pattern of documented diagnostic features and the age of autism identification. J Am Acad Child Adolesc Psychiatry 2013; 52: 401-413.e8.

11. Shattuck PT, Durkin M, Maenner M, et al. Timing of identification among children with an autism spectrum disorder: findings from a populationbased surveillance study. J Am Acad Child Adolesc Psychiatry 2009; 48: 474-483.

12. De Jaco A, Mango D, De Angelis F, et al. Unbalance between excitation and inhibition in phenylketonuria, a genetic metabolic disease associated with autism. Int J Mol Sci 2017; 18: 941-951.

13. Mazlum B, Anlar B, Kalkanoglu-Sivri HS, KarliOguz K, Ozusta S, Unal F. A late-diagnosed phenylketonuria case presenting with autism spectrum disorder in early childhood. Turk J Pediatr 2016; 58: 318-322.

14. Anderson PJ, Wood SJ, Francis DE, et al. Neuropsychological functioning in children with early-treated phenylketonuria: impact of white matter abnormalities. Dev Med Child Neurol 2004; 46: 230-238.

15. Christ SE, Moffitt AJ, Peck D. Disruption of prefrontal function and connectivity in individuals with phenylketonuria. Mol Genet Metab 2010; 99(Suppl 1): S33-S40.

16. Wijburg FA, Wegrzyn G, Burton BK, TylkiSzymanska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/ hyperactivity disorder or autism spectrum disorder. Acta Paediatr 2013; 102: 462-470.

17. Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 2008; 31: 240-252.

18. de Ruijter J, Valstar MJ, Wijburg FA. Mucopolysaccharidosis type III (Sanfilippo syndrome): emerging treatment strategies. Curr Pharm Biotechnol 2011; 12: 923-930.

19. Khan S, Almeciga-Diaz CJ, Sawamoto K, et al. Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab 2017; 120: 78-95.

20. Tomatsu S, Yasuda E, Patel P, et al. Morquio A syndrome: diagnosis and current and future therapies. Pediatr Endocrinol Rev 2014; 12(Suppl 1): 141-151.

21. Harmatz P, Mengel KE, Giugliani R, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab 2013; 109: 54-61.

22. Davison JE, Kearney S, Horton J, Foster K, Peet AC, Hendriksz CJ. Intellectual and neurological functioning in Morquio syndrome (MPS IVa). J Inherit Metab Dis 2013; 36: 323-328.

23. Kury S, Ramaekers V, Bezieau S, Wolf B. Clinical utility gene card for: biotinidase deficiency-update 2015. Eur J Hum Genet 2016; 24. doi: 10.1038/ ejhg.2015.246.

24. Zaffanello M, Zamboni G, Fontana E, Zoccante L, Tato L. A case of partial biotinidase deficiency associated with autism. Child Neuropsychol 2003; 9: 184-188.

25. Uemura T, Ito S, Ohta Y, et al. Abnormal N-glycosylation of a novel missense creatine transporter mutant, G561R, associated with cerebral creatine deficiency syndromes alters transporter activity and localization. Biol Pharm Bull 2017; 40: 49-55.

26. Schulze A, Bauman M, Tsai AC, et al. Prevalence of creatine deficiency syndromes in children with nonsyndromic autism. Pediatrics 2016; 137: e20152672.

27. Schulze A. Creatine deficiency syndromes. Handb Clin Neurol 2013; 113: 1837-1843.

28. Jia F, Cui M, Than MT, Han M. Developmental defects of caenorhabditis elegans lacking branchedchain α-ketoacid dehydrogenase are mainly caused by monomethyl branched-chain fatty acid deficiency. J Biol Chem 2016; 291: 2967-2973.

29. Bindu PS, Shehanaz KE, Christopher R, Pal PK, Ravishankar S. Intermediate maple syrup urine disease: neuroimaging observations in 3 patients from South India. J Child Neurol 2007; 22: 911-913.

30. Swarna M, Jyothy A, Usha Rani P, Reddy PP. Amino acid disorders in mental retardation: a two-decade study from Andhra Pradesh. Biochem Genet 2004; 42: 85-98.